Patents by Inventor Nigel C. Phillips

Nigel C. Phillips has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160151475
    Abstract: The present invention relates to novel bacterial and mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity.
    Type: Application
    Filed: November 30, 2015
    Publication date: June 2, 2016
    Applicant: Telesta Therapeutics IP Inc.
    Inventors: Nigel C. Phillips, Danbing Ke, Zdenek Richard Holan, Mario C. Filion, Mohamed Elrafih, Iqubal Velji
  • Patent number: 9220765
    Abstract: The present invention relates to novel bacterial and mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: December 29, 2015
    Assignee: BIONICHE UROLOGY IP INC.
    Inventors: Nigel C. Phillips, Danbing Ke, Zdenek Richard Holan, Mario C. Filion, Mohamed Elrafih, Iqubal Velji
  • Patent number: 9180176
    Abstract: The present invention relates to novel bacterial and mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: November 10, 2015
    Assignee: Bioniche Urology IP Inc.
    Inventors: Nigel C. Phillips, Danbing Ke, Mario C. Filion, Iqubal Velji
  • Patent number: 9180177
    Abstract: The present invention relates to novel bacterial and mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: November 10, 2015
    Assignee: Bioniche Urology IP Inc.
    Inventors: Nigel C. Phillips, Danbing Ke, Zdenek Richard Holan, Mohamed Elrafih
  • Patent number: 9138469
    Abstract: The present invention relates to novel bacterial and mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: September 22, 2015
    Assignee: Bioniche Urology IP Inc.
    Inventors: Nigel C. Phillips, Danbing Ke, Zdenek Richard Holan, Mohamed Elrafih
  • Publication number: 20150224183
    Abstract: The present invention relates to novel bacterial and mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity.
    Type: Application
    Filed: April 27, 2015
    Publication date: August 13, 2015
    Applicant: Bioniche Urology IP Inc.
    Inventors: Nigel C. Phillips, Danbing Ke, Zdenek Richard Holan, Mario C. Filion, Mohamed Elrafih, Iqubal Velji
  • Patent number: 9044422
    Abstract: The present invention relates to novel mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity. The present invention also relates to a synthetic medium for the cultivation of mycobacteria.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: June 2, 2015
    Assignee: BIONICHE UROLOGY IP INC.
    Inventors: Nigel C. Phillips, Danbing Ke, Zdenek Richard Holan, Mario C. Filion, Mohamed Elrafih, Iqubal Velji
  • Publication number: 20140322372
    Abstract: The present invention relates to novel bacterial and mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity.
    Type: Application
    Filed: February 25, 2014
    Publication date: October 30, 2014
    Applicant: BIONICHE UROLOGY IP INC.
    Inventors: Nigel C. Phillips, Danbing Ke, Zdenek Richard Holan, Mario C. Filion, Mohamed Elrafih, Iqubal Velji
  • Publication number: 20140170189
    Abstract: The present invention relates to novel bacterial and mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity.
    Type: Application
    Filed: February 25, 2014
    Publication date: June 19, 2014
    Applicant: Bioniche Urology IP Inc.
    Inventors: Nigel C. Phillips, Danbing Ke, Zdenek Richard Holan, Mario C. Filion, Mohamed Elrafih, Iqubal Velji
  • Publication number: 20130142828
    Abstract: The present invention relates to novel mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity. The present invention also relates to a synthetic medium for the cultivation of mycobacteria.
    Type: Application
    Filed: October 13, 2011
    Publication date: June 6, 2013
    Applicant: Bioniche Urology IP Inc.
    Inventors: Nigel C. Phillips, Danbing Ke, Zdenek Richard Holan, Mario C. Filion, Mohamed Elrafih, Iqubal Velji
  • Patent number: 8350016
    Abstract: The present invention provides novel synthetic oligonucleotide sequences (hereinafter sequence) of 3 to 9 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases. These sequences optionally further comprise one or more guanine bases or one or more thymine bases, or combinations thereof. The present invention also provides methods of using these compositions to induce responses in cells, and to treat diseases and conditions characterized by undesired cellular proliferation such as autoimmune disease, lymphoproliferative disease, inflammation or cancer.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: January 8, 2013
    Assignee: Bioniche Life Sciences Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion, Zdenek Richard Holan, Stephanie Reader
  • Publication number: 20110160291
    Abstract: The present invention provides novel synthetic oligonucleotide sequences (hereinafter sequence) of 3 to 9 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases. These sequences optionally further comprise one or more guanine bases or one or more thymine bases, or combinations thereof. The present invention also provides methods of using these compositions to induce responses in cells, and to treat diseases and conditions characterized by undesired cellular proliferation such as autoimmune disease, lymphoproliferative disease, inflammation or cancer.
    Type: Application
    Filed: February 7, 2011
    Publication date: June 30, 2011
    Applicant: Bioniche Life Sciences Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion, Zdenek Richard Holan, Stephanie Reader
  • Publication number: 20110111016
    Abstract: The present invention provides compositions comprising synthetic non-DNA base-containing polynucleotide sequences of 3 to 30 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases, in combination with a pharmaceutically acceptable vehicle, particularly one or more adjuvant vehicle, and one or more antigen. The present invention relates to methods of administering these compositions for inducing or modulating an immune response in vitro or in vivo, and particularly for activating antigen presenting cells.
    Type: Application
    Filed: October 8, 2010
    Publication date: May 12, 2011
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Patent number: 7893242
    Abstract: The present invention provides novel synthetic oligonucleotide sequences (hereinafter sequence) of 3 to 9 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases. These sequences optionally further comprise one or more guanine bases or one or more thymine bases, or combinations thereof. The present invention also provides methods of using these compositions to induce responses in cells, and to treat diseases and conditions characterized by undesired cellular proliferation such as autoimmune disease, lymphoproliferative disease, inflammation or cancer.
    Type: Grant
    Filed: January 24, 2007
    Date of Patent: February 22, 2011
    Assignee: Bioniche Life Sciences Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion, Zdenek Richard Holan, Stephanie Reader
  • Patent number: 7662792
    Abstract: A method employing a composition comprising a 2 to 10 base synthetic oligonucleotide sequence selected from the group consisting of (GG)n, (GT)n, a(GT)nb, a(GA)nb, and a(GC)nb, wherein n is an integer between 1 and 3, and a and b are independently either none or one or more As, Cs, Gs, or Ts, or combinations thereof, for modulation of Fas and FasL expression or for modulation of the efficacy of therapeutic agents. The composition is administered to an animal or human with a pharmaceutically acceptable carrier, and optionally with a therapeutic agent, in an amount effective to modulate Fas and FasL expression, to treat the disease, or to modulate efficacy of the therapeutic agent.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: February 16, 2010
    Assignee: Bioniche Life Sciences Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Patent number: 7635686
    Abstract: The present invention provides a composition comprising a 5?-OH, 3?-TEG cholesteryl synthetic sequence wherein the sequence is SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8. The present invention provides methods of using this composition for induction of response in a cell, including but not limited to inhibition of cellular proliferation, induction of cell cycle arrest, induction of caspase activation, cleavage of poly(ADP-ribose) polymerase, induction of apoptosis or modulation of extracellular matrix-cell interactions, or combinations thereof, in cancer cells or synovial cells, and methods of using this composition for treating disease.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: December 22, 2009
    Assignee: Bioniche Life Sciences, Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion, Andrea C. Herréra Gayol
  • Patent number: 7371734
    Abstract: The present invention relates to 3?-OH, 5?-OH polynucleotide sequence compositions and methods for activating an immune response in an individual, and more preferably, for activating antigen presenting cells in the individual. In one embodiment, the antigen presenting cell is a dendritic cell. The present invention also includes compositions and methods for activating dendritic cells in vitro. These dendritic cells may then be administered to an individual. Preferred 3?-OH, 5?-OH polynucleotide sequences comprise six bases wherein at least 50% of the bases are guanine and the 5? base is guanine. The compositions may comprise a phosphodiester or phosphorothioate backbone.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: May 13, 2008
    Assignee: Bioniche Life Sciences Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion
  • Publication number: 20080081793
    Abstract: The present invention provides novel synthetic oligonucleotide sequences (hereinafter sequence) of 3 to 9 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases. These sequences optionally further comprise one or more guanine bases or one or more thymine bases, or combinations thereof. The present invention also provides methods of using these compositions to induce responses in cells, and to treat diseases and conditions characterized by undesired cellular proliferation such as autoimmune disease, lymphoproliferative disease, inflammation or cancer.
    Type: Application
    Filed: January 24, 2007
    Publication date: April 3, 2008
    Applicant: BIONICHE LIFE SCIENCES, INC.
    Inventors: Nigel C. Phillips, Mario C. Filion, Zdenek Richard Holan, Stephanie Reader
  • Patent number: 7200531
    Abstract: The present invention facilitates in silico evaluation of molecules for biological activity by providing a computer-based method to predict whether oligonucleotides may possess biological activity and the efficacy of the biological activity based on the three-dimensional structure and charge characteristics of the oligonucleotides. Biological activities include, but are not limited to, cellular proliferation, induction of cell cycle arrest and apoptosis.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: April 3, 2007
    Assignee: Bionicrie Life Sciences, Inc.
    Inventors: Nigel C. Phillips, Mario C. Filion, Zdenek Richard Holan, Stéphanie Reader
  • Patent number: 7199228
    Abstract: The present invention provides novel synthetic oligonucleotide sequences (hereinafter sequence) of 3 to 9 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases. These sequences optionally further comprise one or more guanine bases or one or more thymine bases, or combinations thereof. The present invention also provides methods of using these compositions to induce responses in cells, and to treat diseases and conditions characterized by undesired cellular proliferation such as autoimmune disease, lymphoproliferative disease, inflammation or cancer.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: April 3, 2007
    Assignee: Bioniche Life Sciences, Inc
    Inventors: Nigel C. Phillips, Mario C. Filion, Zdenek Richard Holan, Stéphanie Reader